All News

From respiratory conditions to rare diseases and beyond, here are 5 groundbreaking FDA approvals from last month.

US foreign aid budget cuts and freezes may potentially increase those affected by tuberculosis in USAID-dependent countries, resulting in millions of lives lost.

Community oncology leaders navigate challenges in value-based care under the Enhancing Oncology Model, facing performance payment uncertainties and evolving drug markets.

Next-generation sequencing shows limited survival benefit but identifies key mutations that may inform future treatment strategies.

Patients with bronchiectasis who are highly symptomatic face an increased risk of future exacerbations, suggesting symptoms should guide prevention strategies.

COVID-19 worsened disparities in cervical cancer screening and HPV vaccine awareness, impacting minority groups with limited access to preventive care.

Participating hospitals in the Prime Vendor Program and the 340B program spent nearly $37.3 billion more on drugs from 2010 to 2021.

Making sure that children have access to high-quality care and parents trust that care is important in making sure that children are cared for after Medicaid cuts take effect.

From 2017 to 2023, women were especially underrepresented in trials in arrhythmia, coronary heart disease, acute coronary syndrome, and heart failure.

Among survey respondents, approximately 80% reported experiencing stigma, including feelings of embarrassment, negative judgment, or being treated differently, because of their condition.

Olivo Adriana, NP, highlights the importance of survivorship care and how providers are utilizing available tools to the best of their ability.

Adults with food insecurity report higher rates of long COVID and lower recovery, with Supplemental Nutrition Assistance Program (SNAP) participation and employment status affecting these associations.

As the prevalence of both chronic kidney disease (CKD) and heart failure (HF) increases, therapies targeting shared pathways are one of the most promising strategies to alter the trajectory of these diseases.

A new report from the National Alliance calls for data transparency and PBM reform to combat rising care costs, enhance equity, and improve well-being.

The drug lowered inflammation, oxidative stress, and endothelial injury markers in women with INOCA and coronary microvascular dysfunction.

Daily potato consumption may improve body composition and vascular health without worsening blood sugar in adults with type 2 diabetes.

DeepSeek-R1 was able to improve diagnosis management in these subspecialties while also lowering operation costs.

The Breast Cancer Index and artificial intelligence–assisted mammograms are tools that can help mitigate symptoms and reassure patient insecurities of women with breast cancer post-treatment.

FDA intensifies efforts against misleading drug advertisements, aiming for transparency and accountability in pharmaceutical marketing practices.

Experts discuss innovative strategies to enhance dental care access in underserved Pennsylvania communities, emphasizing collaboration and cultural sensitivity in outreach efforts.

The use of cemiplimab with chemotherapy showed durable improvements in survival outcomes for non-small cell lung cancer (NSCLC) after 5 years.

FDA expands selumetinib approval to younger children with NF1-related tumors.

Updated results from the MARIPOSA trial show that amivantamab plus lazertinib significantly reduces EGFR- and MET-driven resistance compared with osimertinib.

AD-related outcomes were compared in patients treated with JAK1 inhibitors and IL-13 antibodies, with short-term efficacy biomarkers considered for treatment outcomes.

A study explores how people with psoriasis use digital media, revealing benefits, pitfalls, and gaps in physician-patient communication.

Discover how biomarkers like neurofilament light chain and glial fibrillary acidic protein enhance personalized care for patients who have multiple sclerosis.

Pulse of the Purchaser 2025 survey results showed the use of transparent PBMs more than doubled in just 1 year, from 12% to 31%.

Novel models incorporating tumor deposits outperform tumor TNM in predicting outcomes.